---
title: "Enveric net loss narrows to $3 million in Q2 FY26; loss per share improves to $0.76"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295969831.md"
description: "Enveric Biosciences reported a narrowed Q2 FY26 net loss of $3 million, or $0.76 per share, compared to $11.65 previously. Cash on hand reached $8.3 million, bolstered by recent capital raises. The company advanced IND-enabling work for EB-003, initiating genotoxicity studies ahead of an expected Phase 1 start. CEO Joseph Tucker highlighted new preclinical data supporting the drug's non-hallucinogenic profile."
datetime: "2026-08-14T20:06:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295969831.md)
  - [en](https://longbridge.com/en/news/295969831.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295969831.md)
generator: "portal-rs"
---

# Enveric net loss narrows to $3 million in Q2 FY26; loss per share improves to $0.76

-   Enveric Biosciences posted a net loss attributable to stockholders of $3 million, or $0.76 per share, for Q2 ended June 30, 2026. \* Loss per share narrowed from $11.65 a year earlier; net non-cash expense fell to $300,000 from $500,000. \* Cash on hand totaled $8.3 million at quarter-end; raised $5 million in gross proceeds in offerings and $1.5 million from warrant exercises. \* Advanced IND-enabling work for EB-003, initiating genotoxicity studies ahead of a planned IND submission and expected Phase 1 start. \* CEO Joseph Tucker cited new preclinical data supporting EB-003’s non-hallucinogenic profile, including GloSensor assay results complementing prior BRET findings. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608141605BIZWIRE\_USPR\_\_\_\_\_20260814\_BW007152) on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ENVB.US](https://longbridge.com/en/quote/ENVB.US.md)

## Related News & Research

- [Enveric welcomes final FDA guidance on psychedelic drug trials](https://longbridge.com/en/news/294062160.md)
- [Enveric Biosciences Q2 net loss widens](https://longbridge.com/en/news/295971436.md)
- [Moleculin highlights interim data from pivotal MIRACLE Phase 2/3 Annamycin trial in relapsed/refractory AML](https://longbridge.com/en/news/297191000.md)
- [Zevra Therapeutics presents long-term real-world MIPLYFFA data in Niemann-Pick type C at SSIEM 2026](https://longbridge.com/en/news/296905592.md)
- [SEALSQ subsidiary IC’Alps advances QASIC quantum-resistant ASIC roadmap toward 2026 prototype](https://longbridge.com/en/news/297045515.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**